

**Amendments to the Claims:**

The following listing of claims replaces all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-36. (canceled)

37. (currently amended) A composition of matter comprising as an admixture at least one compound selected from group (i) and at least one compound selected from group (ii),

wherein group (i) consists of:

Group a) consisting of:


tramadol, O-demethyltramadol or O-demethyl-N-mono-demethyl-tramadol,

Group b) consisting of:

- codeine
- dextropropoxyphene
- dihydrocodeine
- diphenoxylate
- ethylmorphine
- meptazinol
- nalbuphine
- pethidine (meperidine)
- tilidine
- tramadol
- viminol
- butorphanol
- dextromoramide
- dezocine
- diacetylmorphine (heroin)

- hydrocodone
- hydromorphone
- ketobemidone
- levomethadone
- levomethadyl-acetate (1- $\alpha$ -acetylmethadol (LAAM))
- levorphanol
- morphine
- nalorphine
- oxycodone
- pentazocine
- piritramide
- alfentanil
- buprenorphine
- etorphine
- fentanyl
- remifentanil
- sufentanil

Group c) consisting of: ☐ 1-phenyl-3-dimethylamino-propane compounds  
corresponding to formula I




wherein

X is chosen from OH, F, Cl, H or OC(O)R<sup>7</sup>, where R<sup>7</sup> is chosen from  
C<sub>1-3</sub>-alkyl, branched or unbranched, saturated or unsaturated,  
unsubstituted or mono- or polysubstituted,

$R^1$  is chosen from  $C_{1-4}$ -alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted,  
 $R^2$  and  $R^3$  in each case independently of one another are chosen from H or  $C_{1-4}$ -alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted, or  
 $R^2$  and  $R^3$  together form a saturated  $C_{4-7}$ -cycloalkyl radical, unsubstituted or mono- or polysubstituted,  
 $R^9$  to  $R^{13}$  in each case independently of one another are chosen from H, F, Cl, Br, I,  $CH_2F$ ,  $CHF_2$ ,  $CF_3$ , OH, SH,  $OR^{14}$ ,  $OCF_3$ ,  $SR^{14}$ ,  $NR^{17}R^{18}$ ,  $SOCH_3$ ,  $SOCF_3$ ;  $SO_2CH_3$ ,  $SO_2CF_3$ , CN,  $COOR^{14}$ ,  $NO_2$ ,  $CONR^{17}R^{18}$ ;  $C_{1-6}$ -alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; phenyl, unsubstituted or mono- or polysubstituted;  
where  $R^{14}$  is chosen from  $C_{1-6}$ -alkyl; pyridyl, thienyl, thiazolyl, phenyl, benzyl or phenethyl, in each case unsubstituted or mono- or polysubstituted;  $PO(O-C_{1-4}\text{-alkyl})_2$ ,  $CO(OC_{1-5}\text{-alkyl})$ ,  $CONH-C_6H_4-(C_{1-3}\text{-alkyl})$ ,  $CO(C_{1-5}\text{-alkyl})$ ,  $CO-CHR^{17}-NHR^{18}$ ,  $CO-C_6H_4-R^{15}$ , where  $R^{15}$  is ortho- $OCOC_{1-3}$ -alkyl or meta- or para- $CH_2N(R^{16})_2$  where  $R^{16}$  is  $C_{1-4}$ -alkyl or 4-morpholino, wherein in the radicals  $R^{14}$ ,  $R^{15}$  and  $R^{16}$  the alkyl groups are branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted;  
where  $R^{17}$  and  $R^{18}$  in each case independently of one another are chosen from H;  $C_{1-6}$ -alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; phenyl, benzyl or phenethyl, in each case unsubstituted or mono- or polysubstituted, or  
 $R^9$  and  $R^{10}$  or  $R^{10}$  and  $R^{11}$  together form an  $OCH_2O$ ,  $OCH_2CH_2O$ ,  $OCH=CH$ ,  $CH=CHO$ ,  $CH=C(CH_3)O$ ,  $OC(CH_3)=CH$ ,  $(CH_2)_4$  or  $OCH=CHO$  ring,

Group d) consisting of [I:] substituted 6-dimethylaminomethyl-1-phenylcyclohexane compounds corresponding to formula II



II

wherein

X is chosen from OH, F, Cl, H or OC(O)R<sup>7</sup>, where R<sup>7</sup> is chosen from C<sub>1-3</sub>-alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted,


R<sup>1</sup> is chosen from C<sub>1-4</sub>-alkyl, benzyl, CF<sub>3</sub>, OH, OCH<sub>2</sub>-C<sub>6</sub>H<sub>5</sub>, O-C<sub>1-4</sub>-alkyl, Cl or F and

R<sup>9</sup> to R<sup>13</sup> in each case independently of one another are chosen from H, F, Cl, Br, I, CH<sub>2</sub>F, CHF<sub>2</sub>, CF<sub>3</sub>, OH, SH, OR<sup>14</sup>, OCF<sub>3</sub>, SR<sup>14</sup>, NR<sup>17</sup>R<sup>18</sup>, SOCH<sub>3</sub>, SOCF<sub>3</sub>; SO<sub>2</sub>CH<sub>3</sub>, SO<sub>2</sub>CF<sub>3</sub>, CN, COOR<sup>14</sup>, NO<sub>2</sub>, CONR<sup>17</sup>R<sup>18</sup>; C<sub>1-6</sub>-alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; phenyl, unsubstituted or mono- or polysubstituted;

where R<sup>14</sup> is chosen from C<sub>1-6</sub>-alkyl; pyridyl, thienyl, thiazolyl, phenyl, benzyl or phenethyl, in each case unsubstituted or mono- or polysubstituted; PO(O-C<sub>1-4</sub>-alkyl)<sub>2</sub>, CO(OC<sub>1-5</sub>-alkyl), CONH-C<sub>6</sub>H<sub>4</sub>-(C<sub>1-3</sub>-alkyl), CO(C<sub>1-5</sub>-alkyl), CO-CHR<sup>17</sup>-NHR<sup>18</sup>, CO-C<sub>6</sub>H<sub>4</sub>-R<sup>15</sup>, where R<sup>15</sup> is ortho-OCOC<sub>1-3</sub>-alkyl or meta- or para-CH<sub>2</sub>N(R<sup>16</sup>)<sub>2</sub> where R<sup>16</sup> is C<sub>1-4</sub>-alkyl or 4-morpholino, wherein in the radicals R<sup>14</sup>, R<sup>15</sup> and R<sup>16</sup> the alkyl

groups are branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; where  $R^{17}$  and  $R^{18}$  in each case independently of one another are chosen from H;  $C_{1-6}$ -alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; phenyl, benzyl or phenethyl, in each case unsubstituted or mono- or polysubstituted, or  $R^9$  and  $R^{10}$  or  $R^{10}$  and  $R^{11}$  together form an  $OCH_2O$ ,  $OCH_2CH_2O$ ,  $OCH=CH$ ,  $CH=CHO$ ,  $CH=C(CH_3)O$ ,  $OC(CH_3)=CH$ ,  $(CH_2)_4$  or  $OCH=CHO$  ring,

Group e) consisting of  $[[[:]]$  6-dimethylaminomethyl-1-phenyl-cyclohexane compounds corresponding to formula III



III

wherein

$X$  is chosen from OH, F, Cl, H or  $OC(O)R^7$ , where  $R^7$  is chosen from  $C_{1-3}$ -alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted, and

$R^9$  to  $R^{13}$  in each case independently of one another are chosen from H, F, Cl, Br, I,  $CH_2F$ ,  $CHF_2$ ,  $CF_3$ , OH, SH,  $OR^{14}$ ,  $OCF_3$ ,  $SR^{14}$ ,  $NR^{17}R^{18}$ ,  $SOCH_3$ ,  $SOCF_3$ ;  $SO_2CH_3$ ,  $SO_2CF_3$ , CN,  $COOR^{14}$ ,  $NO_2$ ,  $CONR^{17}R^{18}$ ;  $C_{1-6}$ -alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; phenyl, unsubstituted or mono- or polysubstituted;

where  $R^{14}$  is chosen from  $C_{1-6}$ -alkyl; pyridyl, thienyl, thiazolyl, phenyl, benzyl or phenethyl, in each case unsubstituted or mono- or polysubstituted;  $PO(O-C_{1-4}$ -alkyl)<sub>2</sub>,  $CO(OC_{1-5}$ -alkyl),  $CONH-C_6H_4-(C_{1-3}$ -alkyl),  $CO(C_{1-5}$ -alkyl),  $CO-CHR^{17}-NHR^{18}$ ,  $CO-C_6H_4-R^{15}$ , where  $R^{15}$  is ortho- $OCOC_{1-3}$ -alkyl or meta- or para- $CH_2N(R^{16})_2$  where  $R^{16}$  is  $C_{1-4}$ -alkyl or 4-morpholino, wherein in the radicals  $R^{14}$ ,  $R^{15}$  and  $R^{16}$  the alkyl groups are branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; where  $R^{17}$  and  $R^{18}$  in each case independently of one another are chosen from H;  $C_{1-6}$ -alkyl, branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; phenyl, benzyl or phenethyl, in each case unsubstituted or mono- or polysubstituted, or

$R^9$  and  $R^{10}$  or  $R^{10}$  and  $R^{11}$  together form an  $OCH_2O$ ,  $OCH_2CH_2O$ ,  $OCH=CH$ ,  $CH=CHO$ ,  $CH=C(CH_3)O$ ,  $OC(CH_3)=CH$ ,  $(CH_2)_4$  or  $OCH=CHO$  ring,

with the proviso that if  $R^9$ ,  $R^{11}$  and  $R^{13}$  correspond to H and one of  $R^{10}$  or  $R^{12}$  corresponds to H and the other corresponds to  $OCH_3$ , X may not be OH, and

wherein group (ii) consists of  $[[:]]$  an anti-muscarine agent selected from the group consisting of  $[[:]]$  atropine, oxybutinin, propiverine, propantheline, emepronium, trospium, tolterodine, darifenacin and  $\alpha,\alpha$ -diphenylacetic acid 4-(N-methylpiperidyl) ester, ~~as well as~~ duloxetine, imipramine and desmopressin, or a salt of any of the foregoing with a physiologically tolerated acid.

38. (currently amended) The composition of matter of claim  $[[36]]$  37, wherein one or more of said at least one compound selected from group (i) and at least one compound selected from group (ii) is present in the form of a free base.

39. (currently amended) The composition of matter of claim ~~[[36]]~~ 37, wherein one or more of said at least one compound selected from group (i) and at least one compound selected from group (ii) is present in the form of a pure enantiomer or pure diastereoisomer.

40. (currently amended) The composition of matter of claim ~~[[36]]~~ 37, wherein one or more of said at least one compound selected from group (i) and at least one compound selected from group (ii) is present in the form of a mixture of stereoisomers.

41. (currently amended) The composition of matter of claim ~~[[36]]~~ 40, wherein one or more of said at least one compound selected from group (i) and at least one compound selected from group (ii) is present in the form of a racemic mixture.

42-43. (canceled)

44. (currently amended) The composition of matter of claim ~~[[36]]~~ 37, wherein said at least one compound selected from group (i) is selected from the group a) consisting of ~~[[:]]~~ tramadol, (+)-O-demethyltramadol and (+)-O-demethyl-N-mono-demethyl-tramadol.

45. (currently amended) The composition of matter of claim ~~[[36]]~~ 37, wherein said at least one compound selected from group (i) is (+)-tramadol.

46. (currently amended) The composition of matter of claim ~~[[36]]~~ 37, wherein said at least one compound selected from group (i) is selected from the group b) consisting of:

- codeine

- dextropropoxyphene
- dihydrocodeine
- diphenoxylate
- ethylmorphine
- meptazinol
- nalbuphine
- pethidine (meperidine)
- tilidine
- viminol
- butorphanol
- dezocine
- nalorphine
- pentazocine, and
- buprenorphine.

47. (currently amended) The composition of matter of claim ~~[[36]]~~ 46, wherein said at least one compound selected from group (i) is selected from the group consisting of:

- codeine
- dextropropoxyphene
- dihydrocodeine
- meptazinol
- nalbuphine
- tilidine, and
- buprenorphine.

48. (currently amended) The composition of matter of claim ~~[[36]]~~ 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein:

X is chosen from the group consisting of OH, F, Cl, OC(O)CH<sub>3</sub> ~~[[or]]~~ and H, ~~[[or]]~~



R<sup>1</sup> is chosen from C<sub>1-4</sub>-alkyl, saturated and unsubstituted, branched or unbranched; [[or]]

R<sup>2</sup> and R<sup>3</sup> independently of one another are chosen from the group consisting of H, and C<sub>1-4</sub>-alkyl, saturated and unsubstituted, branched or unbranched; or R<sup>2</sup> and R<sup>3</sup> together form a C<sub>5-6</sub>-cycloalkyl radical, saturated or unsaturated, unsubstituted or mono- or polysubstituted, [[or]]

R<sup>9</sup> to R<sup>13</sup>, ~~where 3 or 4 of the radicals R<sup>9</sup> to R<sup>13</sup> must correspond to H,~~ are independently of one another are chosen from the group consisting of H, Cl, F, OH, CF<sub>2</sub>H, CF<sub>3</sub> [[or]] and C<sub>1-4</sub>-alkyl, saturated and unsubstituted, branched or unbranched; OR<sup>14</sup> or SR<sup>14</sup>, where R<sup>14</sup> is chosen from C<sub>1-3</sub>-alkyl, saturated and unsubstituted, branched or unbranched; with the proviso that 3 or 4 of the radicals R<sup>9</sup> to R<sup>13</sup> must correspond to H; or

R<sup>12</sup> and R<sup>11</sup> form a 3,4-OCH=CH ring, or

if R<sup>9</sup>, R<sup>11</sup> and R<sup>13</sup> correspond to H, one of R<sup>10</sup> or R<sup>12</sup> also corresponds to H while the other is chosen from [[:]] the group consisting of Cl, F, OH, CF<sub>2</sub>H, CF<sub>3</sub>, OR<sup>14</sup> [[or]] and SR<sup>14</sup>, or

if R<sup>9</sup> and R<sup>13</sup> correspond to H, and R<sup>11</sup> corresponds to OH, OCH<sub>3</sub>, Cl or F, one of R<sup>10</sup> or R<sup>12</sup> also corresponds to H while the other corresponds to OH, OCH<sub>3</sub>, Cl or F, or

if R<sup>9</sup>, R<sup>10</sup>, R<sup>12</sup> and R<sup>13</sup> correspond to H, R<sup>11</sup> is chosen from CF<sub>3</sub>, CF<sub>2</sub>H, Cl or F, or

if R<sup>10</sup>, R<sup>11</sup> and R<sup>12</sup> correspond to H, one of R<sup>9</sup> or R<sup>13</sup> also corresponds to H while the other is chosen from the group consisting of OH, OC<sub>2</sub>H<sub>5</sub> [[or]] and OC<sub>3</sub>H<sub>7</sub>.

49. (currently amended) The composition of matter of claim [[36]] 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein [[:]] X is chosen from the group consisting of OH, F, OC(O)CH<sub>3</sub> [[or]] and H.

50. (currently amended) The composition of matter of claim [[36]] 37, wherein said at least one compound selected from group (i) is selected from the group of

compounds corresponding to formula I wherein ~~[[:]]~~ R<sup>1</sup> is ~~chosen from~~ CH<sub>3</sub>, C<sub>2</sub>H<sub>5</sub>, C<sub>4</sub>H<sub>9</sub> or t-butyl.


51. (currently amended) The composition of matter of claim ~~[[36]]~~ 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein ~~[[:]]~~ R<sup>2</sup> and R<sup>3</sup> independently of one another are chosen from the group consisting of H, CH<sub>3</sub>, C<sub>2</sub>H<sub>5</sub>, i-propyl ~~[[or]]~~ and t-butyl.

52. (currently amended) The composition of matter of claim ~~[[36]]~~ 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein ~~[[:]]~~ R<sup>2</sup> and R<sup>3</sup> together form a C<sub>5-6</sub>-cycloalkyl radical which is saturated and unsubstituted.

53. (currently amended) The composition of matter of claim ~~[[36]]~~ 52, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein ~~[[:]]~~ R<sup>2</sup> and R<sup>3</sup> together form a cyclohexyl group.

54. (currently amended) The composition of matter of claim ~~[[36]]~~ 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula I wherein ~~[[:]]~~ R<sup>9</sup> to R<sup>13</sup> ~~, where 3 or 4 of the radicals R<sup>9</sup> to R<sup>13</sup> must correspond to H,~~ independently of one another are chosen from the group consisting of H, Cl, F, OH, CF<sub>2</sub>H, CF<sub>3</sub>, OCH<sub>3</sub> ~~[[or]]~~ and SCH<sub>3</sub>; with the proviso that 3 or 4 of the radicals R<sup>9</sup> to R<sup>13</sup> must correspond to H.

55. (currently amended) The composition of matter of claim ~~[[47]]~~ 48, wherein compounds corresponding to formula I where R<sup>3</sup> = H are in the form of diastereomers corresponding to formula Ia



and are provided in mixtures with a higher content of this diastereomer compared with the other diastereomer<sub>1</sub> or are provided as a pure diastereomer<sub>1</sub> or compounds corresponding to formula I are provided in the form of the (+)-enantiomer.

56. (currently amended) The composition of matter of claim [[47]] 48, wherein compounds corresponding to formula I, are provided in mixtures with a higher content of the (+)-enantiomer compared with the (-)-enantiomer of a racemic compound or are provided as the pure (+)-enantiomer.

57. (currently amended) The composition of matter of claim [[47]] 48, wherein said at least one compound selected from group (i) is selected from the group consisting of:

- (2RS,3RS)-1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol
- (2R,3R)-1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol,
- (+)-(2R,3R)-1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol,
- (2RS,3RS)-3-(3,4-dichlorophenyl)-1-dimethylamino-2-methyl-pentan-3-ol,
- (2RS,3RS)-3-(3-difluoromethyl-phenyl)-1-dimethylamino-2-methyl-pentan-3-ol,
- (2RS,3RS)-1-dimethylamino-2-methyl-3-(3-methylsulfanyl-phenyl)-pentan-3-ol,
- (3RS)-1-dimethylamino-3-(3-methoxy-phenyl)-4,4-dimethyl-pentan-3-ol,
- (2RS,3RS)-3-(3-dimethylamino-1-ethyl-1-hydroxy-2-methyl-propyl)-phenol,

- (1RS,2RS)-3-(3-dimethylamino-1-hydroxy-1,2-dimethyl-propyl)-phenol,
  - (+)-(1R,2R)-3-(3-dimethylamino-1-hydroxy-1,2-dimethyl-propyl)-phenol,
  - (+)-(1R,2R)-3-(3-dimethylamino-1-hydroxy-1,2-dimethyl-propyl)-phenol,
  - (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol,
  - (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol,
  - (1S,2S)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol,
  - (+)-(1S,2S)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol,
  - (+)-(1R,2R)-acetic acid 3-dimethylamino-1-ethyl-1-(3-methoxy-phenyl)-2-methyl-propyl ester,
  - (1RS)-1-(1-dimethylaminomethyl-cyclohexyl)-1-(3-methoxy-phenyl)-propan-1-ol,
  - (2RS,3RS)-3-(4-chlorophenyl)-1-dimethylamino-2-methyl-pentan-3-ol,
  - (+)-(2R,3R)-3-(3-dimethylamino-1-ethyl-1-hydroxy-2-methyl-propyl)-phenol,
  - (2RS,3RS)-4-dimethylamino-2-(3-methoxy-phenyl)-3-methyl-butan-2-ol, and
  - (+)-(2R,3R)-4-dimethylamino-2-(3-methoxy-phenyl)-3-methyl-butan-2-ol,
- [[or]] and hydrochloride salt ~~of any~~ salts of the foregoing.

58. (currently amended) The composition of matter of claim ~~[[36]]~~ 37, wherein one or more of said at least one compound selected from group (i) is selected from the compounds corresponding to formula II wherein:

X is chosen from the group consisting of OH, F, Cl, OC(O)CH<sub>3</sub> ~~[[or]]~~ and H, ~~[[or]]~~

R<sup>1</sup> is ~~chosen from~~ C<sub>1-4</sub>-alkyl, CF<sub>3</sub>, OH, O-C<sub>1-4</sub>-alkyl, Cl or F, ~~[[or]]~~

R<sup>9</sup> to R<sup>13</sup>, ~~where 3 or 4 of the radicals R<sup>9</sup> to R<sup>13</sup> must correspond to H,~~

independently of one another are chosen from the group consisting of H, Cl, F, OH, CF<sub>2</sub>H, CF<sub>3</sub> ~~[[or]]~~ and C<sub>1-4</sub>-alkyl, saturated and unsubstituted, branched or unbranched; OR<sup>14</sup> or SR<sup>14</sup>, where R<sup>14</sup> is chosen from C<sub>1-3</sub>-alkyl, saturated and unsubstituted, branched or unbranched; with the proviso that 3 or 4 of the radicals R<sup>9</sup> to R<sup>13</sup> must correspond to H; or

R<sup>12</sup> and R<sup>11</sup> form a 3,4-OCH=CH ring, or

if R<sup>9</sup>, R<sup>11</sup> and R<sup>13</sup> correspond to H, one of R<sup>10</sup> or R<sup>12</sup> also corresponds to H while the other is chosen from ~~[[:]]~~ the group consisting of Cl, F, OH, CF<sub>2</sub>H, CF<sub>3</sub>, OR<sup>14</sup> ~~[[or]]~~ and SR<sup>14</sup>, or

if R<sup>9</sup> and R<sup>13</sup> correspond to H, and R<sup>11</sup> corresponds to OH, OCH<sub>3</sub>, Cl or F, one of R<sup>10</sup> or R<sup>12</sup> also corresponds to H while the other corresponds to OH, OCH<sub>3</sub>, Cl or F, or

if R<sup>9</sup>, R<sup>10</sup>, R<sup>12</sup> and R<sup>13</sup> correspond to H, R<sup>11</sup> is ~~chosen from~~ CF<sub>3</sub>, CF<sub>2</sub>H, Cl or F, or  
if R<sup>10</sup>, R<sup>11</sup> and R<sup>12</sup> correspond to H, one of R<sup>9</sup> or R<sup>13</sup> also corresponds to H while the other is ~~chosen from~~ OH, OC<sub>2</sub>H<sub>5</sub> or OC<sub>3</sub>H<sub>7</sub>.

59. (currently amended) The composition of matter of claim ~~[[36]]~~ 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula II wherein ~~[[:]]~~ X is ~~chosen from~~ OH, F or H.


60. (currently amended) The composition of matter of claim ~~[[36]]~~ 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula II wherein ~~[[:]]~~ R<sup>1</sup> is ~~chosen from~~ OH, CF<sub>3</sub> or CH<sub>3</sub>.

61. (currently amended) The composition of matter of claim ~~[[36]]~~ 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula II wherein:

R<sup>9</sup> to R<sup>13</sup>, ~~where 3 or 4 of the radicals R<sup>9</sup> to R<sup>13</sup> must correspond to H,~~  
independently of one another are chosen from the group consisting of H, Cl, F, OH, CF<sub>2</sub>H, CF<sub>3</sub>, OCH<sub>3</sub> or SCH<sub>3</sub>, with the proviso that 3 or 4 of the radicals R<sup>9</sup> to R<sup>13</sup> must correspond to H, or

if R<sup>9</sup>, R<sup>11</sup> and R<sup>13</sup> correspond to H, one of R<sup>10</sup> or R<sup>12</sup> also corresponds to H while the other is ~~chosen from~~ OH, CF<sub>2</sub>H, OR<sup>14</sup> or SCH<sub>3</sub>.

62. (currently amended) The composition of matter of claim ~~[[57]] 58,~~ wherein the compounds corresponding to formula II are in the form of diastereomers corresponding to formula IIa



IIa

and are provided in mixtures with a higher content of this diastereomer compared with the other diastereomer, or are provided as a pure diastereomer, or compounds corresponding to formula II are provided in the form of the (+)-enantiomer.

63. (currently amended) The composition of matter of claim ~~[[57]] 58,~~ wherein compounds corresponding to formula II are provided in mixtures with a higher content of the (+)-enantiomer compared with the (-)-enantiomer of a racemic compound or are provided in the form of the pure (+)-enantiomer.

64. (currently amended) The composition of matter of claim ~~[[57]] 58,~~ wherein said at least one compound selected from group (i) is selected from the group consisting of:

- (1R,3R,6R)-6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol,
- (+)-(1R,3R,6R)-6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol,

- (1RS,3RS,6RS)-6-dimethylaminomethyl-1-(3-hydroxy-phenyl)-cyclohexane-1,3-diol,
- (1RS,3SR,6RS)-6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol,
- (+)-(1R,2R,5S)-3-(2-dimethylaminomethyl-1-hydroxy-5-methyl-cyclohexyl)-phenol, and
- (1RS,2RS,5RS)-3-(2-dimethylaminomethyl-1-hydroxy-5-trifluoromethyl-cyclohexyl)-phenol,

[[or a]] and hydrochloride salt of any salts of the foregoing.

65. (currently amended) The composition of matter of claim ~~[[36]]~~ 37, wherein one or more of said at least one compound selected from group (i) is selected from the compounds corresponding to formula III wherein:

X is chosen from the group consisting of OH, F, Cl, OC(O)CH<sub>3</sub> ~~[[or]]~~ and H, ~~[[or]]~~ R<sup>9</sup> to R<sup>13</sup>, ~~where 3 or 4 of the radicals R<sup>9</sup> to R<sup>13</sup> must correspond to H,~~

independently of one another are chosen from the group consisting of H, Cl, F, OH, CF<sub>2</sub>H, CF<sub>3</sub> ~~[[or]]~~ C<sub>1-4</sub>-alkyl, saturated and unsubstituted, branched or unbranched; OR<sup>14</sup> ~~[[or]]~~ and SR<sup>14</sup>, where R<sup>14</sup> is chosen from C<sub>1-3</sub>-alkyl, saturated and unsubstituted, branched or unbranched; with the proviso that 3 or 4 of the radicals R<sup>9</sup> to R<sup>13</sup> must correspond to H; or

R<sup>12</sup> and R<sup>11</sup> form a 3,4-OCH=CH ring, or

if R<sup>9</sup>, R<sup>11</sup> and R<sup>13</sup> correspond to H, one of R<sup>10</sup> or R<sup>12</sup> also corresponds to H while the other is ~~chosen from~~ Cl, F, OH, SH, CF<sub>2</sub>H, CF<sub>3</sub>, OR<sup>14</sup> or SR<sup>14</sup>, or

if R<sup>9</sup> and R<sup>13</sup> correspond to H and R<sup>11</sup> corresponds to OH, OCH<sub>3</sub>, Cl or F, one of R<sup>10</sup> or R<sup>12</sup> also corresponds to H while the other corresponds to OH, OCH<sub>3</sub>, Cl or F, or

if R<sup>9</sup>, R<sup>10</sup>, R<sup>12</sup> and R<sup>13</sup> correspond to H, R<sup>11</sup> is ~~chosen from~~ CF<sub>3</sub>, CF<sub>2</sub>H, Cl or F, or


if R<sup>10</sup>, R<sup>11</sup> and R<sup>12</sup> correspond to H, one of R<sup>9</sup> or R<sup>13</sup> also corresponds to H while the other is ~~chosen from~~ OH, OC<sub>2</sub>H<sub>5</sub> or OC<sub>3</sub>H<sub>7</sub>.

66. (currently amended) The composition of matter of claim ~~[[36]]~~ 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula III wherein ~~[[:]]~~ X is ~~chosen from~~ OH, F or H.

67. (currently amended) The composition of matter of claim ~~[[36]]~~ 37, wherein said at least one compound selected from group (i) is selected from the group of compounds corresponding to formula III wherein:

~~R<sup>9</sup> to R<sup>13</sup>, where 3 or 4 of the radicals R<sup>9</sup> to R<sup>13</sup> must correspond to H,~~  
independently of one another are chosen from the group consisting of H, Cl, F, OH, CF<sub>2</sub>H, CF<sub>3</sub>, OCH<sub>3</sub> ~~[[or]]~~ and SCH<sub>3</sub>, with the proviso that 3 or 4 of the radicals R<sup>9</sup> to R<sup>13</sup> must correspond to H; or  
if R<sup>9</sup>, R<sup>11</sup> and R<sup>13</sup> correspond to H, one of R<sup>10</sup> or R<sup>12</sup> also corresponds to H while the other is ~~chosen from~~ OH, CF<sub>2</sub>H, OR<sup>14</sup> or SCH<sub>3</sub>.

68. (currently amended) The composition of matter of claim ~~[[64]]~~ 65, wherein the compounds corresponding to formula III are in the form of diastereomers corresponding to formula IIIa



IIIa

and are provided in mixtures with a higher content of this diastereomer compared with the other diastereomer, or are provided as a pure diastereomer, or compounds corresponding to formula III are provided in the form of the (+)-enantiomer.



69. (currently amended) The composition of matter of claim ~~[[64]]~~ 65, wherein compounds corresponding to formula III, are provided in mixtures with a higher content of the (+)-enantiomer compared with the (-)-enantiomer of a racemic compound or are provided in the form of the pure (+)-enantiomer.

70. (currently amended) The composition of matter of claim ~~[[64]]~~ 65, wherein said at least one compound selected from group (i) is selected from the group consisting of:

- (+)-(1R,2R)-3-(2-dimethylaminomethyl-1-fluoro-cyclohexyl)-phenol,
  - (+)-(1S,2S)-3-(2-dimethylaminomethyl-cyclohexyl)-phenol or
  - (1S,2S)-3-(2-dimethylaminomethyl-cyclohexyl)-phenol or
  - (-)-(1R,2R)-3-(2-dimethylaminomethyl-cyclohexyl)-phenol,
  - (1R,2R)-3-(2-dimethylaminomethyl-cyclohexyl)-phenol,
  - (-)-(1R,2R)-[2-(3-methoxy-phenyl)-cyclohexylmethyl]-dimethylamine, and
  - (1R,2R)-[2-(3-methoxy-phenyl)-cyclohexylmethyl]-dimethylamine,
- ~~[[or a]]~~ and hydrochloride salt of any salts of the foregoing.

71. (currently amended) The composition of matter of claim ~~[[36]]~~ 37, wherein said at least one compound selected from group (ii) is selected from the group consisting of: darifenacin, duloxetine, oxybutinin and tolterodine.

72. (currently amended) The composition of matter of claim ~~[[36]]~~ 37, wherein said at least one compound selected from group (ii) is selected from the group consisting of: oxybutinin and tolterodine.

73. (currently amended) A pharmaceutical formulation comprising as an active compound combination a composition of matter according to claim ~~[[36]]~~ 37 and ~~suitable additives or auxiliary substances~~ at least one pharmaceutically suitable additive or auxiliary substance.